<img src="https://ml-eu.globenewswire.com/Resource/Download/4e957060-eef5-4c1b-81e6-73683a4daa1e?size=2" nborder="0" align="left" hspace="5" vspace="5" title="INVENTIVA" alt="INVENTIVA"/>Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site: <a href="https://www.globenewswire.com/Tracker?data=HjalE9-YKvAbuuhgy1XztvI3q4u6C8SSv1FrZ2XeOXw3N84VbtaIysgKmSIV4JZEp2NBLz6S2MTzhEyPXA3kQ3s2xfoX4bZ9L-LgnxX4YKQ=" rel="nofollow" target="_blank" title="www.inventivapharma.com">www.inventivapharma.com</a> <table style="border-collapse: collapse; margin-left:auto; margin-right:auto; width:646px; border-collapse:collapse ;"><tr><td style="width:103.47px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Date</td><td style="width:198px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Number of Shares Outstanding</td><td style="width:180px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Total Voting Rights, Gross (1)</td><td style="width:164.8px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Total Voting Rights, Net (2)</td></tr><tr><td style="width:103.47px;;text-align: center ; vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">May 22, 2026</td><td style="width:198px;;text-align: center ; vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">209 007 475</td><td style="width:180px;;text-align: center ; vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">218 082 368</td><td style="width:164.8px;;text-align: center ; vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">218 082 368</td></tr></table> <ol><li style="margin-top:0in; margin-bottom:0in; text-align:justify;">The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. </li></ol> <ol><li style="margin-top:0in; margin-bottom:0in; text-align:justify;" value="2">The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed.</li></ol> About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). <a href="https://www.globenewswire.com/Tracker?data=7Ld2yYsvxkmuy6BdS4KjFipwtHpGzzjtEo9Viu990oynPMkvq3NFIou3WKLbAgd0x1zlpkgoSr4MfWUXeSB3LIXrI0-7VysIHjVu7t3YQG9hLQ5h8HmHOogE_8sLx5q8" rel="nofollow" target="_blank" title="">https://www.inventivapharma.com</a>   Contacts <table style="border-collapse: collapse; width:800px; border-collapse:collapse ;"><tr><td style="width:314px;;vertical-align: top ; ">Media Relations Pascaline Clerc: <a href="mailto:media@inventivapharma.com" rel="nofollow" target="_blank" title="media@inventivapharma.com">media@inventivapharma.com</a> Mark Corbae: <a href="mailto:inventivapr@icrhealthcare.com" rel="nofollow" target="_blank" title="inventivapr@icrhealthcare.com">inventivapr@icrhealthcare.com</a>  </td><td style="width:314px;;vertical-align: top ; ">Investor Relations David Nikodem: <a href="mailto:IR@inventivapharma.com" rel="nofollow" target="_blank" title="IR@inventivapharma.com">IR@inventivapharma.com</a> Patricia L. Bank: <a href="mailto:patti.bank@icrhealthcare.com" rel="nofollow" target="_blank" title="patti.bank@icrhealthcare.com">patti.bank@icrhealthcare.com</a>  </td></tr></table>
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-bF5gDIhQQg_C6VdXZjWKuFGrZA1K2v-3gGYAJaK-Fi8Zpt9s3rhn10v52L_ej1_T9iG1kscSa7dgEbPcicwO6YPgm-Z6qXQY3Wch-VqMGN6aAUTBcn48Xm_jIvYC_uFrr0eeBK-ts8NZnO427wNQF7KFLI8XwNzGSH2LxIZPqJztFtC4F3Euoc_a6jOAnVbNeSdosGhruHO-WR1UTfCxQ==" title="Inventiva - PR - Voting Rights - EN - 06 09 2026" rel="nofollow">Inventiva - PR - Voting Rights - EN - 06 09 2026</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/MDQ4MmYzMTctNzEwNy00ZTU1LTk2N2ItNmVlOTcxODU2ODA5LTEwOTM4MjAtMjAyNi0wNi0wOS1lbg==/tiny/INVENTIVA.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn